DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT) was the target of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 366,700 shares, a drop of 70.9% from the November 15th total of 1,260,000 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 141,300 shares, the short-interest ratio is currently 2.6 days.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright lifted their target price on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. StockNews.com started coverage on shares of DBV Technologies in a report on Sunday. They issued a “hold” rating for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a report on Tuesday.

DBV Technologies Stock Down 4.6 %

NASDAQ DBVT traded down $0.16 during trading hours on Wednesday, hitting $3.29. 1,310,093 shares of the company were exchanged, compared to its average volume of 51,000. The company has a 50 day moving average of $3.45 and a two-hundred day moving average of $4.04. The firm has a market cap of $67.68 million, a price-to-earnings ratio of -0.75 and a beta of 0.64. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $10.70.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.